NDAORALSUSPENSION
Approved
Jan 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DILANTIN-125 (phenytoin) by Viatris is cytochrome p450 1a2 inducers [moa]. First approved in 1953.
Drug data last refreshed 4h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DILANTIN-125 is a phenytoin oral suspension, a cytochrome P450 1A2 inducer used as an anti-epileptic agent approved in 1953. It prevents and treats convulsions by stabilizing neuronal membranes and reducing seizure propagation. The drug is available as an oral suspension formulation for easier dosing in patients who cannot swallow tablets.
$0.186MPart D
LOE ApproachingDeclining
Minimal growth opportunity; teams supporting this product are likely focused on lifecycle management and transition planning rather than expansion.
Mechanism of Action
Cytochrome P450 1A2 Inducers
Pharmacologic Class:
Anti-epileptic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
Started Aug 2026
30 enrolled
Healthy Participants
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
Started Jun 2026
30 enrolled
Healthy Volunteers
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
Started Apr 2025
37 enrolled
Healthy Volunteers
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
Started Mar 2025
14 enrolled
Healthy
A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers
Started Aug 2024
30 enrolled
Not Determined
Worked on DILANTIN-125 at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.